- Home
- QNRX vs TCRT Comparison
QNRX vs TCRT Comparison
Compare QNRX & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- TCRT
- Stock Information
- Founded
- QNRX 2018
- TCRT 1998
- Country
- QNRX United States
- TCRT United States
- Employees
- QNRX N/A
- TCRT N/A
- Industry
- QNRX Medical/Dental Instruments
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- TCRT Health Care
- Exchange
- QNRX Nasdaq
- TCRT Nasdaq
- Market Cap
- QNRX 2.5M
- TCRT 2.5M
- IPO Year
- QNRX N/A
- TCRT N/A
- Fundamental
- Price
- QNRX $7.12
- TCRT $2.63
- Analyst Decision
- QNRX
- TCRT
- Analyst Count
- QNRX 0
- TCRT 0
- Target Price
- QNRX N/A
- TCRT N/A
- AVG Volume (30 Days)
- QNRX 355.0K
- TCRT 1.5M
- Earning Date
- QNRX 05-08-2025
- TCRT 05-14-2025
- Dividend Yield
- QNRX N/A
- TCRT N/A
- EPS Growth
- QNRX N/A
- TCRT N/A
- EPS
- QNRX N/A
- TCRT N/A
- Revenue
- QNRX N/A
- TCRT $10,000.00
- Revenue This Year
- QNRX N/A
- TCRT $5,680,500.00
- Revenue Next Year
- QNRX N/A
- TCRT N/A
- P/E Ratio
- QNRX N/A
- TCRT N/A
- Revenue Growth
- QNRX N/A
- TCRT 100.00
- 52 Week Low
- QNRX $5.01
- TCRT $1.31
- 52 Week High
- QNRX $54.95
- TCRT $14.20
- Technical
- Relative Strength Index (RSI)
- QNRX 46.54
- TCRT 54.55
- Support Level
- QNRX $5.27
- TCRT $2.27
- Resistance Level
- QNRX $7.22
- TCRT $2.93
- Average True Range (ATR)
- QNRX 1.12
- TCRT 0.40
- MACD
- QNRX 0.22
- TCRT -0.05
- Stochastic Oscillator
- QNRX 62.79
- TCRT 33.04
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.